Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACCESS THE SEGMENT HERE HOUSTON, TX / ACCESS NEWSWIRE / JUNE 8, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES ADDRESSING SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT PARTICIPATED IN A VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT. STEVE O'LOUGHLIN, CHIEF FINANCIAL OFFICER OF CNS PHARMACEUTICALS, DISCUSSED THE COMPANY'S RECENTLY COMPLETED OVERSUBSCRIBED $22.5 MILLION FINANCING IN THE VIRTUAL SEGMENT, ADDRESSING THE FACTORS THAT ENABLED THE SUCCESSFUL CAPITAL RAISE FOLLOWING ITS STRATEGIC RESET AND ACQUISITION-FOCUSED TRANSFORMATION.

CNS PHARMACEUTICALS CFO, STEVE O'LOUGHLIN, HIGHLIGHTS COMPANY'S RECENT $22.5M FINANCING IN VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT

ACCESS THE CEO CONNECT SEGMENT HERE HOUSTON, TX / ACCESS NEWSWIRE / MAY 20, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES ADDRESSING SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT PARTICIPATED IN A VIRTUAL INVESTOR CEO CONNECT SEGMENT. AS PART OF THE SEGMENT, RAMI LEVIN, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CNS PHARMACEUTICALS, HIGHLIGHTED THE COMPANY'S RECENT $22.5 MILLION FINANCING, INCLUDING ITS STRATEGIC PIVOT, PROGRESS MADE TO DATE AND HOW THE CAPITAL POSITIONS CNS TO IDENTIFY AND ADVANCE NEW ASSETS AIMED AT DRIVING LONG-TERM SHAREHOLDER VALUE.

CNS PHARMACEUTICALS CEO, RAMI LEVIN, PARTICIPATES IN VIRTUAL INVESTOR CEO CONNECT SEGMENT HIGHLIGHTING COMPANY'S RECENT STRATEGIC TRANSFORMATION PROGRESS

OVERSUBSCRIBED $22.5 MILLION FINANCING ANTICIPATED TO ENABLE CNS PHARMACEUTICALS TO ACQUIRE DIFFERENTIATED, CLINICAL-STAGE ASSETS WITH IDENTIFIABLE NEAR-TERM VALUE-INFLECTION CATALYSTS, ALIGNED WITH ITS RECENTLY ANNOUNCED CORPORATE STRATEGY COMPANY ACTIVELY EVALUATING MULTIPLE ACQUISITION OPPORTUNITIES WHILE ADVANCING DISCUSSIONS TO OUT-LICENSE ITS LEGACY GLIOBLASTOMA MULTIFORME PROGRAMS, BERUBICIN AND TPI-287 NEW EXECUTIVE LEADERSHIP TEAM ASSEMBLED IN THE FIRST QUARTER CONTINUES TO DEMONSTRATE RAPID EXECUTION AGAINST STRATEGY HOUSTON, TX / ACCESS NEWSWIRE / MAY 14, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES ADDRESSING SIGNIFICANT UNMET MEDICAL NEEDS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE HIGHLIGHTING THE COMPANY'S ONGOING STRATEGIC TRANSFORMATION AND EXECUTION PROGRESS. THE FIRST QUARTER OF 2026 MARKED THE BEGINNING OF A SIGNIFICANT STRATEGIC SHIFT FOR CNS PHARMACEUTICALS, INCLUDING THE APPOINTMENT OF A NEW CHIEF EXECUTIVE OFFICER AND EXECUTIVE LEADERSHIP TEAM, THE LAUNCH OF A NEW CORPORATE STRATEGY, THE REPOSITIONING OF THE COMPANY TOWARD AN ACQUISITION-DRIVEN GROWTH STRATEGY FOCUSED ON DIFFERENTIATED CLINICAL-STAGE ASSETS IN NEUROLOGY AND ONCOLOGY AND THE DECISION TO SEEK OUT-LICENSING OPPORTUNITIES FOR ITS LEGACY GLIOBLASTOMA MULTIFORME PROGRAMS, BERUBICIN AND TPI-287.

CNS PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS STRATEGIC TRANSFORMATION PROGRESS

THE PRIVATE PLACEMENT INCLUDES PARTICIPATION FROM SEVERAL LEADING HEALTHCARE INVESTORS INCLUDING ADAR1 CAPITAL, IKARIAN CAPITAL, STONEPINE CAPITAL MANAGEMENT AND NAZARE PARTNERS PROCEEDS EXPECTED TO ENABLE CNS PHARMACEUTICALS TO ACQUIRE DIFFERENTIATED, CLINICAL-STAGE ASSETS WITH IDENTIFIABLE NEAR-TERM VALUE-INFLECTION CATALYSTS, ALIGNED WITH ITS RECENTLY ANNOUNCED CORPORATE STRATEGY HOUSTON, TX / ACCESS NEWSWIRE / MAY 4, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES ADDRESSING SIGNIFICANT UNMET MEDICAL NEEDS, ANNOUNCED TODAY THAT IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS FOR A PRIVATE PLACEMENT FINANCING THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $22.5 MILLION TO THE COMPANY, BEFORE PLACEMENT AGENT FEES AND OFFERING EXPENSES. THE PRIVATE PLACEMENT INCLUDES PARTICIPATION FROM INSTITUTIONAL HEALTHCARE INVESTORS, INCLUDING ADAR1 CAPITAL, IKARIAN CAPITAL, STONEPINE CAPITAL MANAGEMENT AND NAZARE PARTNERS.

CNS PHARMACEUTICALS ANNOUNCES OVERSUBSCRIBED $22.5 MILLION PRIVATE PLACEMENT FINANCING

NEWLY FORMED EXECUTIVE TEAM INITIATES GLOBAL SEARCH FOR DIFFERENTIATED THERAPEUTIC ASSETS FOR NEUROLOGY AND ONCOLOGY INDICATIONS, TWO OF BIOPHARMA'S LARGEST AND FASTEST-GROWING MARKETS STRATEGIC TRANSFORMATION DRIVEN BY A COMPREHENSIVE DATA ANALYSIS WILL ENABLE NEW EXECUTIVE TEAM TO LEVERAGE DECADES OF EXPERIENCE IN THESE THERAPEUTIC AREAS COMPANY PIVOTING FROM A SINGULAR FOCUS ON GLIOBLASTOMA AND WILL EXPLORE OUT-LICENSING OF LEGACY ASSETS BERUBICIN AND TPI 287 HOUSTON, TX / ACCESS NEWSWIRE / MARCH 11, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) (THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES IN HIGH-VALUE NEUROLOGY AND ONCOLOGY MARKETS, TODAY ANNOUNCED THAT IT HAS LAUNCHED A NEW CORPORATE GROWTH STRATEGY DESIGNED TO BUILD A HIGH-VALUE PIPELINE IN NEUROLOGY AND ONCOLOGY. THE STRATEGY IS BEING LED BY THE NEWLY FORMED EXECUTIVE TEAM WITH DEEP EXPERIENCE ACROSS NEUROLOGY, ONCOLOGY AND RARE DISEASE DRUG DEVELOPMENT.

CNS PHARMACEUTICALS LAUNCHES NEW CORPORATE STRATEGY FOCUSED ON BUILDING A HIGH-VALUE NEUROLOGY AND ONCOLOGY PIPELINE

DR. KELLEY ADDS TWO DECADES OF HIGHLY RELEVANT DRUG DEVELOPMENT AND REGULATORY STRATEGY EXPERIENCE SPANNING ONCOLOGY, RARE DISEASES AND CNS NEWLY FORMED EXECUTIVE TEAM IS COMMITTED TO EXECUTION AND COMPANY EVOLUTION FOCUSED ON PATIENT AND STAKEHOLDER VALUE HOUSTON, TX / ACCESS NEWSWIRE / MARCH 2, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THE APPOINTMENT OF LYNNE KELLEY, MD, FACS, AS CHIEF MEDICAL OFFICER. DR. KELLEY BRINGS MORE THAN TWO DECADES OF GLOBAL LEADERSHIP EXPERIENCE ACROSS CLINICAL DEVELOPMENT, TRANSLATIONAL MEDICINE AND REGULATORY STRATEGY IN ONCOLOGY, RARE DISEASES, CNS AND MEDICAL DEVICES.

CNS PHARMACEUTICALS APPOINTS LYNNE KELLEY, MD, FACS, AS CHIEF MEDICAL OFFICER, COMPLETING EXECUTIVE LEADERSHIP TEAM

NEW MEMBERS OF THE STRENGTHENED LEADERSHIP TEAM ADD DECADES OF OPERATIONAL EXECUTION, PIPELINE OPTIMIZATION AND TRANSACTIONAL EXPERTISE TO SUPPORT COMPANY GROWTH AND VALUE CREATION HOUSTON, TX / ACCESS NEWSWIRE / FEBRUARY 17, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THE COMPANY'S RECENTLY APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER, RAMI LEVIN, IN CLOSE ALIGNMENT WITH THE BOARD OF DIRECTORS, HAS RECRUITED KEY MEMBERS TO HIS NEW EXECUTIVE TEAM. THESE NEW APPOINTMENTS, WHICH WILL BE EFFECTIVE MARCH 2, 2026, WILL HELP DRIVE THE COMPANY'S EVOLUTION.

CNS PHARMACEUTICALS APPOINTS MULTIPLE KEY EXECUTIVES TO DRIVE COMPANY'S RECENTLY INITIATED STRATEGIC TRANSFORMATION

NEWLY APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER, RAMI LEVIN, DISCUSSES PLANS FOR A NEW ERA AT CNS PHARMACEUTICALS STRATEGIC FOCUS, PIPELINE OPTIMIZATION AND FORMALIZING ROADMAP FOR NEAR AND LONG-TERM VALUE CREATION HOUSTON, TX / ACCESS NEWSWIRE / JANUARY 27, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ISSUED A LETTER TO SHAREHOLDERS FROM ITS NEWLY APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER, RAMI LEVIN. DEAR FELLOW SHAREHOLDERS, I AM HONORED TO WRITE TO YOU FOR THE FIRST TIME IN MY ROLE AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CNS PHARMACEUTICALS.

CNS PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS

INDUSTRY VETERAN RAMI LEVIN, MBA APPOINTED AS PRESIDENT & CHIEF EXECUTIVE OFFICER HOUSTON, TX / ACCESS NEWSWIRE / DECEMBER 17, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED JOHN CLIMACO HAS STEPPED DOWN AS CHIEF EXECUTIVE OFFICER OF CNS PHARMACEUTICALS AND RAMI LEVIN, MBA, HAS BEEN APPOINTED AS PRESIDENT & CHIEF EXECUTIVE OFFICER. MR. LEVIN BRINGS NEARLY 30 YEARS OF GLOBAL LEADERSHIP EXPERIENCE ACROSS ONCOLOGY, NEUROLOGY, RARE DISEASES, ENDOCRINOLOGY, AND CELL AND GENE THERAPY, WITH A PROVEN TRACK RECORD OF SCALING ORGANIZATIONS, ADVANCING LATE-STAGE CLINICAL PROGRAMS, AND DRIVING TRANSFORMATIVE VALUE CREATION.

CNS PHARMACEUTICALS ANNOUNCES CEO TRANSITION

CASH EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2026 COMPANY FOCUSED ON ADVANCING NEXT-GENERATION ANTI-CANCER THERAPIES DERIVED FROM WELL-ESTABLISHED DRUG CLASSES, NOW ENGINEERED TO CROSS THE BLOOD-BRAIN BARRIER, POTENTIALLY ENHANCING EFFICACY FOR PATIENTS LEAD PROGRAM, TPI 287, PROGRESSING TOWARD PHASE 2 STUDY FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM), ONE OF THE MOST AGGRESSIVE TYPES OF BRAIN CANCER, WITH A MEDIAN SURVIVAL OF ONLY AROUND 15 MONTHS FROM THE TIME OF DIAGNOSIS HOUSTON, TX / ACCESS NEWSWIRE / NOVEMBER 17, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDED A CORPORATE UPDATE. "AS WE HEAD INTO THE FINAL QUARTER OF THE YEAR, OUR MISSION REMAINS CENTERED ON DELIVERING MEANINGFUL DEVELOPMENTS FOR PATIENTS BATTLING BRAIN AND CNS CANCERS.

CNS Pharmaceuticals, Inc.

CNSP

Price

Financial Reports

No items found.

Press Releases

CNS Pharmaceuticals, Inc.

CNSP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CNSP